Minerva Surgical, Inc. (UTRS)

Market Cap	4.08M
Revenue (ttm)	51.69M
Net Income (ttm)	-35.55M
Shares Out	8.88M
EPS (ttm)	-4.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,328
Open	0.510
Previous Close	0.510
Day's Range	0.450 - 0.550
52-Week Range	0.300 - 14.000
Beta	0.68
Analysts	Buy
Price Target	20.00 (+4,247.83%)
Earnings Date	Nov 13, 2023

About UTRS

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure moni...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 174
• Stock Exchange: OTCMKTS
• Ticker Symbol: UTRS

Financial Performance

In 2022, UTRS's revenue was $50.29 million, a decrease of -3.47% compared to the previous year's $52.10 million. Losses were -$34.11 million, 58.9% more than in 2021.

Analyst Forecast

According to one analyst, the rating for UTRS stock is "Buy" and the 12-month stock price forecast is $20.0.

Price Target

$20.0

(4,247.83% upside)

Analyst Consensus: Buy